BioMedPartners
Finance · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
734 Walt Whitman Rd Ste 103, Melville, N...Phone Number
+41 612703500Website
www.biomedvc.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About BioMedPartners
BioMed Partners (www.biomedvc.com), based in Basel, Switzerland is an independent venture capital firm that has established itself as a leading investor in early-stage biotech companies in Europe. In its third fund, raised in 2002, BioMed Partners focuses on the build-up of companies with highly innovative assets and technology platforms as well as on strong, entrepreneurial teams. The first investment of BioMedInvest III was in the Swiss immuno-oncology company Amal SA (Geneva) in 2017, which was subsequently acquired by Boehringer Ingelheim in June 2019.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioMedPartners your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if BioMedPartners is spiking on competitors!
Earning: See what the market has to say on BioMedPartners recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at BioMedPartners
Check if BioMedPartners has recently received funding, and reach out quickly before it becomes old news!
BioMedPartners, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once BioMedPartners has new funding data
Product Launch: Get notified when BioMedPartners launches new products
Website visits: Recent activity has been detected on your website
Click to see if BioMedPartners had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at BioMedPartners
Find 2 more new buyers
Compare Similar Companies to BioMedPartners
Compare insights from companies similar to BioMedPartners, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
BioMedPartners
<$5M
1-10
Private
-
2002
N/A
Company Profile Activity
Activity Insights
BioMedPartners is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
BioMedPartners is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about BioMedPartners.
Most Recent Scoops
Project
Spending/Investment
Project
Spending/Investment
Project
Spending/Investment
Project
Spending/Investment
Project
Spending/Investment
BioMedPartners News & Media
iDEL Therapeutics Launches with €9 Million Seed Financing Led by BiomedVC to Advance Oncology Pipeline Based on Direct Cytosolic Transfer Technology
Newly launched biotech company iDEL Therapeutics is pioneering a pipeline of cancer drugs that are delivered directly into the cytosol of tumor cellsTubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies
MUNICH--(BUSINESS WIRE)--Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+. All existing investors also participated in the round, including Bayern Kapital (with Wachstumsfonds Bayern 2), BioMedPartners, coparion, High-Tech Gründerfonds (HTGF), OCCIDENT and Seventure Partners. The new capital will be used to advance Tubulis’ proprietary pipeline of uniquely assemblScenic Biotech Announces $31 Million Financing to Progress Pipeline of Genetic Modifiers in Cancer and Rare Diseases
AMSTERDAM, March 10, 2022 /PRNewswire/ -- Scenic Biotech BV ("Scenic"), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, is pleased to announce it has closed a Series A...Noema Pharma raises CHF54 million in Series A financing round led by Sofinnova Partners and ...
In-licensing of four clinical-stage product candidates to treat orphan neurological disordersHighly experienced team leverages latest scientific...
Read more news
Top Finance Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioMedPartners
Sign Up For FreeTo access detailed company insights
BioMed Partners (www.biomedvc.com), based in Basel, Switzerland is an independent venture capital firm that has established itself as a leading investor in early-stage biotech companies in Europe. In its third fund, raised in 2002, BioMed Partners focuses on the build-up of companies with highly innovative assets and technology platforms as well as... Read More
